Radavirsen

Drug Profile

Radavirsen

Alternative Names: AVI-7100; AVI-7376

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator AVI BioPharma
  • Developer National Institute of Allergy and Infectious Diseases; Sarepta Therapeutics
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Genetic transcription inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in USA (IV, Infusion)
  • 01 Jun 2016 Sarepta Therapeutics and the National Institute of Allergy and Infectious Diseases complete a Phase-I trial for Influenza A virus infections (in volunteers) in USA (NCT01747148)
  • 30 Sep 2014 Sarepta completes a single ascending dose part of a phase I study in healthy volunteers; the Independent Data and Safety Monitoring Board recommends the study to continue as planned
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top